ClinicalTrials.gg
RecruitingNCT05241405QISEINUpdated Oct 1, 2024

Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast or Gynecological Cancer

An interventional study of QISENG and PLACEBO in Breast Cancer and Fatigue, sponsored by Centre Francois Baclesse. Recruiting at 10 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Centre Francois Baclesse · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
354
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Breast Neoplasms by Centre Francois Baclesse — 4 open to participants now, 5 under way, none of them phase 3. Breast Neoplasms · Centre Francois Baclesse.

Planned enrollment
3rd of 19
354 · median 75
Started
2022
with 1 other
No phase
12 of 23
3 open now
Registered
18th of 23
by date

Among the 23 studies in Breast Neoplasms by Centre Francois Baclesse, this one is the 3rd largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2022, is one of 12 with no phase, and was the 18th registered.

Breast Neoplasms

14,848 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 23 studies in Breast Neoplasms by Centre Francois Baclesse are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Breast Neoplasms by Centre Francois Baclesse, or all of them as a file.
02

Study summary

This is a multicenter randomized trial in breast cancer patients reporting cancer-related fatigue to evaluate the efficacy and safety of Qiseng® based on extract of American ginseng combined with vitamin C from extract of Camu Camu berries

03

Conditions studied

  • Breast Cancer
  • Fatigue

Keywords

  • Qiseng
  • food supplement
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with localized breast or gynecological cancer treated as curative and/or neoadjuvant chemotherapy and/or adjuvant radiotherapy. These treatments must have been completed within 6 months of inclusion.

    • Patient reporting a chronic, stable fatigue state at investigator assessment, defined as a fatigue score ≥ 4 on the visual analog scale rated up to 10, experienced for at least one month
    • Maintenance therapy with hormone therapy or other maintenance therapy (trastuzumab, bevacizumab...) is allowed before and/or during the study (except for pembrolizumab, abemaciclib and PARP inhibitors, which are not authorized)
    • Patient 18 years of age or older
    • Effective in women of childbearing age
    • Patient affiliated to a social security plan
    • Signed

Exclusion criteria

Exclusion Criteria:

  • Other identified causes of fatigue (anemia of grade > 2, underlying chronic disease known to be associated with fatigue)
  • Ongoing chemotherapy (patients scheduled for oral capecitabine or trastuzumab-emtasin in the setting are not eligible)
  • breast or gynecological cancer
  • Ongoing treatment with a tyrosine kinase inhibitor or other P-gp transported molecule or Pembrolizumab or PARP inhibitors
  • Patient requiring oral diabetes therapy
  • Regular intake of Vitamin C (in addition to what is provided by the diet)
  • Patients with chronic pain requiring daily treatment with analgesics, anti-inflammatory drugs or
  • Consumption of ginseng-based products in the month prior to inclusion
  • to any of the components of Qiseng or placebo
  • Pregnant or breastfeeding patient
  • Simultaneous participation in another therapeutic clinical trial (trial using an experimental product)
  • Patient deprived of liberty, under guardianship or curatorship
  • Patient unable to undergo the medical follow-up of the trial for geographical, social or psychopathological reasons
  • History of any other malignant disease during the last 3 years, except for skin cancer other than melanoma, carcinoma in situ of the uterus. Any other solid tumor or lymphoma (without bone marrow involvement) must have been treated and show no signs of recurrence for at least 3 years
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
354 participants (estimated)

Study arms

  • Experimental
    Qiseng

    200 mg/capsule of P. quinquefolius extract, i.e. 30 mg of ginsenosides, associated with 30 mg of vitamin C extracted from Camu Camu berry

    Dietary Supplement: QISENG

  • Placebo comparator
    Placebo

    neutral microgranules of Qiseng® excipients without P. quinquefolius or Camu Camu extract

    Dietary Supplement: PLACEBO

Interventions

  • Dietary supplementQISENG

    2 capsules/day for 8 weeks.

  • Dietary supplementPLACEBO

    2 capsules/day for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Fatigue score change [min :5; max:20]

    The difference between the initial (inclusion) score and the best score based on EORTC QLQ-FA12 questionnaire (physical fatigue dimension) between assessments at 1 week (S9) and 4 weeks (S12) after the end of treatment) will be calculated

    Time frame: After 1 week and 4 weeks after the end of treatment (so 8 weeks of treatment)

Secondary outcomes

  1. Other dimensions of fatigue [min :12; max:48]

    Score of emotional fatigue, cognitive fatigue, global score, according to the EORTC QLQ-FA12 self-questionnaire

    Time frame: after 4 weeks of treatment, after 8 weeks of treatment and 4 weeks after the end of treatment

  2. The incidence of treatment-related adverse events

    The incidence of treatment-related adverse events and the number of patients in whom at least one treatment-related adverse event occurred

    Time frame: up to 8 weeks after the end of treatment

  3. Quality of life level assessed by EORTC QLQ-C30 questionnaire

    EORTC QLQ-C30 quality of life questionnaire scores

    Time frame: 4 and 8 weeks of treatment and 4 weeks after the end of treatment

  4. anxiety level

    HADS anxiety and depression questionnaire scores

    Time frame: after 4 and 8 weeks of treatment, and 4 weeks after the end of treatment

  5. Cognitive function

    Cognitive function dimensions, according to the FACT-Cog self-assessment questionnaire,

    Time frame: after 4 and 8 weeks of treatment and 4 weeks after the end of treatment

  6. Physical activity level

    measured by the IPAQ questionnaire scores

    Time frame: after 4 and 8 weeks of treatment, and again 4 weeks after the end of treatment

  7. Sleep quality

    measured by CAT-sleep questionnaire scores

    Time frame: after 4 and 8 weeks of treatment and 4 weeks after the end of treatment

  8. The level of acceptability of the treatment,

    measured by the total number of times the treatment was taken

    Time frame: over a period of 8 weeks

07

Study locations

5 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Sep 2027, 60 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 60 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2022
First posted
Feb 15, 2022
StartActual
Sep 27, 2022
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05241405
Collaborators
NATSUCA laboratory, Groupement Interrégional de Recherche Clinique et d'Innovation
Responsible party
Sponsor
First posted
Feb 15, 2022
Start date
Sep 27, 2022
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 1, 2024

Study contacts

Carine SEGURA, MD
Contact
c.segura@baclesse.unicancer.fr
+33231455050
Alexandra LECONTE
Contact
a.leconte@baclesse.unicancer.fr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion